Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program
PharmacoEconomics · 2024-11 · 42 (11) · 1279-1286
DOI: 10.1007/s40273-024-01426-3 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PharmacoEconomics, online erschienen am 21.08.2024. Verfasst von Snigdha Gulati und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of General and Thoracic Surgery, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Drugs, Generic, Medicare Part D, Drug Costs, Cost Savings. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of General and Thoracic Surgery, Cleveland Clinic, Cleveland, OH, USA.
- Department of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
- Faculty of Arts and Sciences, Harvard University, Cambridge, MA, USA.
- Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
- Department of Surgery, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
- Department of Surgery, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, GRB 425, Boston, MA, 02114, USA. dagarwal@mgh.harvard.edu.
ORCID-Profile: Divyansh Agarwal
Zitieren
APA
Gulati, S., Gupta, M., Yan, T., Yelamanchili, S., Xu, L. Q., Bharani, T., Naji, A., & Agarwal, D. (2024). Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program. PharmacoEconomics, 42(11), 1279-1286. https://doi.org/10.1007/s40273-024-01426-3
Vancouver
Gulati S, Gupta M, Yan T, Yelamanchili S, Xu LQ, Bharani T, et al. Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program. PharmacoEconomics. 2024;42(11):1279-1286. doi:10.1007/s40273-024-01426-3
BibTeX
@article{Gulati2024,
author = {Gulati, Snigdha and Gupta, Mohak and Yan, TingTing and Yelamanchili, Sneha and Xu, Lucy Qinghua and Bharani, Tina and Naji, Ali and Agarwal, Divyansh},
title = {Drug Pricing Stewardship from Mark Cuban’s Cost Plus Generic Drug Program},
journal = {PharmacoEconomics},
year = {2024},
volume = {42},
number = {11},
pages = {1279--1286},
doi = {10.1007/s40273-024-01426-3}
}
EUVIMED